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Effects of single-nucleotide polymorphisms in MTHFR and
MTRR on mortality and allograft loss in kidney transplant re-
cipients.
Background. Plasma total homocysteine (tHcy) is associated
with cardiovascular outcomes in kidney transplant recipients
(KTR). The methylenetetrahydrofolate-reductase (MTHFR)
677C>T polymorphism, an important determinant of plasma
tHcy concentrations, could therefore constitute an important
prognostic marker.
Methods. We prospectively followed 710 KTR over >6 years.
The MTHFR677C>T, MTHFR1298A>C, MTHFR1793G>A,
and MTRR66A>G polymorphisms were analyzed. Demo-
graphic, clinical, and transplant-related information was ob-
tained, and patients were followed-up using the Austrian
Dialysis and Transplant Registry. Using Cox regression, we es-
tablished the independent relations of each genotype to the risk
of death from any cause, and/or kidney allograft loss.
Results. During a median follow-up of 6.1 years, 154 par-
ticipants died and 260 kidney allografts were lost. Compared
to patients with the MTHFR677CC genotype, patients with
MTHFR677CT had an adjusted relative mortality risk of 1.02
(95%CI 0.70–1.47), and those with MTHFR677TT of 0.98
(95%CI 0.52–1.85). Compared to MTHFR677CC, the rela-
tive risks of kidney allograft loss were 0.93 (95%CI 0.70–1.23;
MTHFR677CT) and 0.78 (95%CI 0.47–1.30; MTHFR677TT),
respectively. None of the other genotypes were associated with
the risks studied, either. These findings did not depend on
whether we controlled for tHcy levels.
Conclusion. This study does not support the routine use of
MTHFR or MTRR genotyping for prognostic evaluation or
risk-stratification in kidney transplant recipients.
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Elevated plasma total homocysteine (tHcy) is a pow-
erful risk factor for several adverse outcomes, such as
congestive heart failure, ischemic heart disease, stroke,
cardiovascular and all-cause mortality in the general pop-
ulation, as well as in other subpopulations [1–5]. Re-
cently, associations between tHcy and arteriosclerotic
events (composite end point of coronary heart disease,
stroke/cerebrovascular disease, and abdominal aortic or
lower extremity arterial disease) and with all-cause mor-
tality have been described in kidney transplant recipi-
ents (KTR) [6, 7]. Homozygosity for a C>T transition
in the gene encoding 5,10-methylenetetrahydrofolate re-
ductase (MTHFR 677C>T, MTHFR 677TT genotype)
is an established determinant of higher tHcy plasma
levels both in subjects with normal and reduced renal
function [8–10]. Some investigators have suggested that
genetic determinants of homocysteine metabolism such
as MTHFR 677C>T may be more meaningful markers
of prognostic relevance [11]. Only limited information
is available on the putative association between such
polymorphisms and patient or graft survival in KTR.
One study examined the association between MTHFR
677C>T and kidney allograft survival in 336 KTR pa-
tients over three years of follow-up [12]. However, that
study did not reveal an effect of this genetic variant on
kidney allograft survival [12]. Another study also failed
to detect any associations between MTHFR 677C>T or
MTHFR 1298A>C and mortality, but was limited by
even smaller sample size (N = 183) and shorter follow-
up (2.3 years) [13]. To fill this void, we conducted the
present study. We sought to examine the associations be-
tween MTHFR 677C>T and patient or allograft survival
in KTR (primary hypotheses). We also tested the associa-
tions between two other single nucleotide polymorphisms
of MTHFR and a polymorphism in the methionine syn-
thase reductase (MTRR) gene and these outcomes (sec-
ondary hypotheses).
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METHODS
Study population and data collection
Between 1996 and 1998, we prospectively enrolled into
this study 733 stable KTR who received routine follow-
up at the transplant clinic of the Vienna General Hos-
pital. All patients gave informed consent in accordance
with the Declaration of Helsinki and the Austrian Law on
Gene Technology, and the study was approved by the In-
stitutional Review Board. At baseline, we assessed each
patient’s age, gender, the underlying renal disease that
likely caused the kidney failure, number of previous kid-
ney transplants, time from first renal replacement therapy
(RRT) to transplantation, and time since the most recent
kidney transplantation. Body mass index was calculated
as the weight in kilograms divided by the squared height
in meters. The immunosuppressive regimen at study base-
line was also recorded.
During the baseline visit, blood was drawn from each
patient for laboratory analysis. Total plasma homocys-
teine was measured using standard methods as described
previously [9]. Furthermore, we measured each patient’s
total cholesterol, triglyceride, C-reactive protein, and cre-
atinine level. We then used the Cockcroft-Gault formula
to estimate the glomerular filtration rate (GFR) [14],
which was standardized to a body surface area of 1.73m2.
From the registry of the Eurotransplant Foundation,
the joint organ procurement agency for Austria, Belgium,
Germany, Luxemburg, The Netherlands, and Slovenia,
we obtained information on the organ donor (donor
age, gender, living vs. cadaveric donor) and on the spe-
cific circumstances of the transplantation procedure [cold
ischemia time, number and type of human leukocyte
antigen (HLA)-mismatch, and recipient panel reactive
antibody (PRA)-titer]. Longitudinal information on all
dialysis patients and KTR residing in Austria is rou-
tinely collected by the Austrian Dialysis and Transplant
Registry (OeDTR). Follow-up in this database has been
100% complete for many years, and reliable information
on timing and occurrence of patient death and modality
switches, such as reinitiation of maintenance dialysis after
kidney graft failure, is available for study.
The outcomes of this study were all-cause mortality
and kidney allograft loss; the latter was defined as the
composite end point of patient death and reinitiation of
maintenance dialysis. Patients remained in the mortality
risk set even after loss of transplant function. Additional
analyses using graft failure as the main outcome, but using
death as a censoring rather than an outcome event, were
also conducted.
Genotyping
Identification of the 677C>T transition and of the
1298A>C transversion in MTHFR was performed by re-
striction fragment length polymorphism (RFLP) analy-
sis using the polymerase chain reaction (PCR) primers
and the restriction enzymes Hinf I and Fnu4 HI pub-
lished by Frosst et al and Weisberg et al [15–17]. The
1793G>A mutation was analyzed in PCR products that
had been amplified with the primers published by Rady
et al using the restriction enzyme Bsrb I [18]. For anal-
ysis of MTRR 66A>G, we used a modified protocol of
the RFLP described by Wilson et al, including a new an-
tisense primer and the restriction enzyme Nsp I [19, 20].
All samples showing the homozygous mutant genotype
were retested in an independent RFLP analysis. We also
calculated the allele frequencies for the three mutations
in the study population and tested for violations of the
Hardy-Weinberg equilibrium assumption [21].
Statistical analyses
All patients were followed from the date of study inclu-
sion until they reached an end point, or the date they were
last seen at the transplant clinic. Univariate and multivari-
ate Cox proportional hazards models were then fit to test
for potential risk factors of the outcomes. The measure
of association was the hazards ratio (HR) accompanied
by the corresponding 95% confidence interval (CI). We
developed the tests of our hypotheses by first examining
the univariate associations between each SNP and the
outcomes of interest. Heterozygosity and homozygosity
for MTHFR 1793G>A had to be combined because only
two patients were homozygous for that variant. Next, we
built multivariate models of all outcomes using an auto-
mated variable selection process that has been described
previously [7]. Body mass index was used in five cate-
gories since the associations between this variable and all
outcomes of this study are known to be U-shaped [22,
23]. Recipient age and gender, as well as estimated GFR,
were forced into all models. From there, we introduced
all other variables individually and then assessed whether
they confounded the association between the main ex-
posure variable (defined as a change in the regression
coefficient >10%), in which case the variable would be in-
cluded regardless of the significance level. We then added
all indicator variables for the four polymorphisms to be
tested. We took multiple testing into account by using
the P value adjustment described by Bonferroni. A pri-
ori, we decided to not include tHcy in the multivariate
models because we considered this variable to likely be
on the causal pathway between these polymorphisms and
outcomes. We used SAS for Windows (release 8.2, SAS
Corporation, Cary, NC, USA) software for all statistical
analyses.
RESULTS
From the 733 patients originally included in the study,
seven were found to receive their routine transplant
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Table 1. Baseline characteristics of 710 kidney transplant recipients
MTHFR 677 genotype
Variable CC CT TT
N (%) or mean (± SD) (N = 334) (N = 298) (N = 78)
Recipient age years 51.8 (±13.2) 52.0 (±13.4) 54.8 (±12.8)
Recipient gender male 199 (59.6%) 184 (61.7%) 44 (56.4%)
Glomerular filtration rate mL/min/1.73m2 55.3 (±19.8) 56.4 (±20.0) 55.4 (±21.2)
Body mass index kg/m2 25.4 (±4.3) 25.5 (±4.3) 25.3 (±3.9)
Total plasma homocysteine lmol/L 15.9 (±7.2) 17.1 (±7.9) 22.5 (±14.8)
Plasma folate concentration nmol/L 15.4 (±6.3) 14.5 (±12.4) 11.7 (±8.6)
Plasma vitamin B12 concentration pmol/L 253 (±136) 263 (±176)a 237 (±125)
Total cholesterol mg/dL 235 (±61) 233 (±52) 233 (±47)
Triglycerides mg/dL 205 (±191) 188 (±112) 170 (±85)
C-reactive protein mg/dL
≤0.5 267 (80.4%) 211 (72.0%) 53 (68.0%)
0.5–1.0 36 (10.8%) 39 (13.3%) 11 (14.1%)
>1.0 29 (8.7%) 43 (14.7%) 14 (18.0%)
Underlying renal disease
Diabetic nephropathy 23 (6.9%) 16 (5.4%) 8 (10.3%)
Glomerulonephritis 126 (37.7%) 99 (33.2%) 18 (23.1%)
Interstitial nephritis 44 (13.2%) 62 (20.8%) 8 (10.3%)
Polycystic kidney disease 52 (15.6%) 30 (8.4%) 15 (19.2%)
Various other, specified 29 (8.7%) 25 (8.4%) 5 (6.4%)
Unspecified/unknown 60 (20.0%) 66 (22.2%) 24 (30.8%)
SD, standard deviation. C-reactive protein was unavailable for 7 patients.
aExcludes one patient who had excessively high vitamin B12 concentrations, presumably from vitamin substitution.
Table 2. Transplantation-related characteristics of study cohort
MTHFR 677 genotype
Variable CC CT TT
N (%) or mean (± SD) (N = 334) (N = 298) (N = 78)
Immunosuppressive regimen
Cyclosporine A + Corticosteroid + Azathioprine 161 (48.2%) 120 (40.3%) 36 (46.2%)
Cyclosporine A + Corticosteroid 85 (25.5%) 83 (27.9%) 17 (21.8%)
Cyclosporine A + Corticosteroid + MMF 62 (18.6%) 49 (16.4%) 15 (19.2%)
Other 26 (7.8%) 46 (15.4%) 10 (12.8%)
Time from first RRT to transplantation years 3.2 (±3.8) 3.1 (±3.3) 3.1 (±3.7)
Time since transplantation years 4.8 (±3.8) 5.1 (±4.2) 4.8 (±4.1)
Number of previous kidney transplants
0 277 (82.9%) 237 (79.5%) 62 (79.5%)
1 48 (14.4%) 52 (17.5%) 13 (16.7%)
2/3 9 (2.7%) 9 (3.0%) 3 (3.8%)
Donor organ type living versus cadaveric 16 (4.8%) 15 (5.0%) 2 (2.6%)
Donor age years 38.2 (±16.1) 38.7 (±15.2) 38.0 (±15.4)
Donor gender male 202 (60.5%) 201 (67.5%) 46 (59.0%)
Number of HLA-mismatches 2.2 (±1.2) 2.1 (±1.1) 2.1 (±1.3)
Cold ischemia time hours 20.9 (±7.7) 21.0 (±7.7) 19.7 (±7.2)
Panel reactive antibody titer >50% vs. ≤50% 23 (6.9%) 19 (6.4%) 5 (6.4%)
Abbreviations: SD, standard deviation; HLA, human leukocyte antigen; RRT, renal replacement therapy; MMF, mycophenolate.
care outside Austria and were excluded. For 16 patients,
information on their donors was unavailable from the
Eurotransplant Foundation registry. The remaining 710
patients constituted the final study cohort. The mean age
was 52.2 years, 60.1% were men, and the mean estimated
GFR was 55.8 mL/min/1.73m2. Other baseline character-
istics are listed in Table 1. On average, patients had re-
ceived their current transplant five years prior to enroll-
ment; see Table 2 for a listing of transplantation-related
characteristics of the study cohort.
Of the 710 patients in the cohort, 334 (47.0%)
showed the wild-type of the MTHFR 677C>T poly-
morphism (MTHFR677CC genotype), while 298 patients
(42.0%) were heterozygous (MTHFR677CT), and 78
(11%) were homozygous (MTHFR677CT; Table 3). No
MTHFR 1298A>C mutation was found in 316 patients
(44.5%; MTHFR1298AA), 328 patients (46.2%) were
heterozygous (MTHFR1298AC), and 66 (9.3%) were ho-
mozygous individuals (MTHFR1298CC). The MTHFR
1793G>A polymorphism was relatively rare: 639 (90.0%)
showed wild-type alleles (MTHFR1793GG), 69 (9.7%)
were heterozygous (MTHFR1793GA), and only two pa-
tients were homozygous (MTHFR1793AA). One hun-
dred and thirty-nine patients (19.6%) tested negative
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Table 3. Distribution of MTHFR and MTRR genotypes in study
cohort
N (%) Hardy-Weinberg
Enzyme-Genotype Total = 710 Equilibrium, P =
MTHFR 677 CCa 334 (47.0%)
CT 298 (42.0%)
TT 78 (11.0%) 0.37
MTHFR 1298 AAa 316 (44.5%)
AC 328 (46.2%)
CC 66 (9.3%) 0.10
MTHFR 1793 GGa 639 (90.0%)
GA 69 (9.7%)
AA 2 (0.3%) 0.80
MTRR 66 AAa 139 (19.6%)
AG 355 (50.0%)
GG 216 (30.4%) 0.26
Abbreviations: MTHFR, methylenetetrahydrofolate-reductase; MTRR,
methionine synthase reductase.
a Wild-type.
for MTRR 66A>G (MTRR66AA), 355 patients (50.0%)
were heterozygous (MTRR66AG), and 216 (30.4%) were
homozygous for the mutation (MTRR66GG). The condi-
tions of Hardy-Weinberg equilibrium were not violated
in any of the four polymorphisms (Table 3).
End point: All-cause mortality
During a median follow-up of 6.1 years (3798 person-
years; py), 154 patient deaths were recorded (crude in-
cidence rate 40.6/1000 py). From a Kaplan-Meier plot
of cumulative survival stratified by MTHFR 677C>T
genotype, there was no indication of an association be-
tween this polymorphism and all-cause mortality (log-
rank test: P < 0.93, not shown). From univariate Cox
proportional hazards models, compared to patients with-
out this mutation, the relative mortality risk of patients
with the MTHFR677CT genotype was 1.03 (95% CI 0.74–
1.43; P = 0.88). Homozygosity (MTHFR677TT) was as-
sociated with a relative mortality risk of 0.92 (95% CI
0.53–1.61; Table 4). After multivariate adjustment, the
estimated relative mortality risks to MTHFR677CC re-
mained practically unchanged (MTHFR677CT: HR 1.02;
95% CI 0.70–1.47); MTHFR677TT: HR 0.98; 95% CI
0.52–1.85). Similarly, we did not find any associations be-
tween the three other polymorphisms and all-cause mor-
tality. The detailed results are listed in Table 4.
End point: Kidney allograft loss
We had 3480 person-years of follow-up available for
the study of allograft loss (alive or associated with death),
and this event was observed in 260 patients (crude inci-
dence rate 74.7/1000 py). As before, the Kaplan-Meier
plot of cumulative allograft loss failed to indicate any as-
sociation between MTHFR 677C>T genotype and this
end point (log-rank test, P = 0.75, not shown). The uni-
variate Cox proportional hazards model revealed that the
relative risk of patients with the MTHFR677CT geno-
type to lose their kidney allograft was 0.99 (95% CI
0.76–1.28) compared with MTHFR677CC. The relative
risk of patients with MTHFR677TT was 0.83 (95% CI
0.53–1.28). Multivariate model adjustment did not ma-
terially change these associations: compared to patients
with the MTHFR677CC genotype, the relative risks for
MTHFR677CT patients were 0.93 (95% CI 0.70–1.23),
and for MTHFR677TT patients 0.78 (95% CI 0.47–1.30).
Similarly, no associations between MTHFR 1298A>C,
MTHFR 1793G>A, or MTRR 66A>G and kidney allo-
graft loss were found (see Table 5).
Next, we conducted analyses that used death as a cen-
soring rather than an event indicator, the only outcome
now being resumption of dialysis, which was observed
in 157 patients (none of the patients received preemp-
tive retransplantation). No associations between any of
the genotypes of study and death-censored allograft loss
were found (results not shown).
DISCUSSION
From this large prospective study, we found that
four common polymorphisms of two enzymes that are
involved in homocysteine metabolism, MTHFR and
methionine synthase reductase (MTRR), were not asso-
ciated with all-cause mortality or kidney allograft loss.
These results arose from multivariate Cox regression
models that simultaneously controlled for several impor-
tant confounders and predictors of the outcomes under
study. To our knowledge, this is the largest prospective
study of the putative associations between these poly-
morphisms and such outcomes in KTR to date.
Homocysteine is a well-established risk factor for car-
diovascular outcomes in the general population [1, 2]. As-
sociations between elevated fasting tHcy plasma concen-
trations and all-cause mortality, cardiovascular outcomes,
and—maybe—allograft loss have also been described
in KTR [6, 7, 24]. In this context, the putative asso-
ciation between the MTHFR 677C>T polymorphism
and mortality is of particular interest. Homozygosity for
MTHFR677TT was strongly and independently associ-
ated with tHcy plasma levels in KTR [9]. In KTR, there
was a 3.7 lmol/L (95% CI 1.84–5.45) greater mean tHcy
concentration in patients with the MTHFR677TT geno-
type compared to patients with the MTHFR677CC geno-
type [25]. Thus, it has been hypothesized that elevated
tHcy measured at any one point in time may not reflect
lifetime tHcy exposure, and that MTHFR 677C>T geno-
type, constant over a lifetime, may be a more meaning-
ful marker of mortality or cardiovascular risk [11]. This
was the primary hypothesis of the present study, but we
were unable to substantiate the proposed association be-
tween MTHFR 677C>T and long-term outcomes. No as-
sociation of MTHFR 677C>T with overall mortality has
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Table 4. Association between MTHFR and MTRR genotypes and all-cause mortalitya
Univariate Multivariate
Enzyme-Genotype Hazards Ratio 95% CI P value Hazards Ratio 95% CI P value
MTHFR 677 CC Referent – – Referent – –
CT 1.03 0.74–1.43 0.88 1.02 0.70–1.47 0.93
TT 0.92 0.53–1.61 0.77 0.98 0.52–1.85 0.95
MTHFR 1298 AA Referent – – Referent – –
AC 1.24 0.88–1.73 0.22 1.15 0.78–1.69 0.48
CC 1.51 0.89–2.56 0.13 1.21 0.65–2.25 0.54
MTHFR 1793 GG Referent – – Referent – –
GA/AA 1.32 0.82–2.14 0.26 1.34 0.80–2.24 0.26
MTRR 66 AA Referent – – Referent – –
AG 1.02 0.67–1.55 0.93 1.01 0.66–1.56 0.95
GG 1.05 0.67–1.67 0.83 1.07 0.67–1.71 0.77
aMultivariate model additionally adjusted for recipient age, gender, estimated glomerular filtration rate, C-reactive protein, body mass index, diabetic nephropathy,
donor gender, time from first renal replacement therapy to transplantation.
Table 5. Association between MTHFR and MTRR genotypes and kidney allograft lossb
Univariate Multivariate
Enzyme-Genotype Hazards Ratio 95% CI P value Hazards Ratio 95% CI P value
MTHFR 677 CC Referent – – Referent – –
CT 0.99 0.76–1.28 0.92 0.93 0.70–1.23 0.59
TT 0.83 0.53–1.28 0.39 0.78 0.47–1.30 0.34
MTHFR 1298 AA Referent – – Referent – –
AC 1.14 0.88–1.48 0.31 1.07 0.80–1.43 0.66
CC 1.24 0.81–1.90 0.32 0.95 0.57–1.57 0.84
MTHFR 1793 GG Referent – – Referent – –
GA/AA 1.31 0.89–1.91 0.17 1.27 0.85–1.91 0.24
MTRR 66 AA Referent – – Referent – –
AG 1.11 0.80–1.54 0.52 1.12 0.80–1.57 0.52
GG 0.99 0.69–1.42 0.96 1.06 0.73–1.54 0.75
bMultivariate model additionally adjusted for recipient age, gender, estimated glomerular filtration rate, C-reactive protein, body mass index, and diabetic
nephropathy, time from first renal replacement therapy to transplantation.
recently been reported in 417 hemodialysis and 44 peri-
toneal dialysis patients [26].
Three other studies examined the possible associa-
tion between MTHFR 677C>T genotype and patient
or kidney allograft survival [12, 13, 27]. Neither study
found an association, but all were limited by small num-
bers of enrollees and short follow-up (336 KTR over
three years [12], 183 KTR over 2.3 years [13], and 165
KTR over one year [27], respectively). Despite a sizeable
study population and long follow-up (710 KTR over >6
years), we were unable to refute the null hypothesis of no
association.
In light of our recent findings of an association between
total homocysteine concentrations and all-cause mortal-
ity in this cohort, the lack of an association between a
major determinant of total plasma homocysteine levels,
MTHFR 677C>T homozygosity, is slightly surprising. It is
known that homocysteine concentrations are influenced
by several factors, MTHFR 677 genotype being only one
of many. Other characteristics such as age or kidney func-
tion are also strongly correlated with homocysteine con-
centrations, but are also determinants of cardiovascular
mortality. It is possible that homocysteine is a mere sur-
rogate for cardiovascular risk, but not causally related
to these outcomes. Of course, causality has not been es-
tablished for the associations between homocysteine and
cardiovascular outcomes in any population [28].
There is currently no evidence supporting an asso-
ciation between tHcy and the other polymorphisms
of study, MTHFR 1298A>C, MTHFR 1793G>A, and
MTRR 66A>G. Therefore, testing for associations be-
tween these polymorphisms and the outcomes of study
would have merely been hypothesis-generating. In the
study population, no direct associations were found be-
tween MTHFR 1298A>C or MTRR 66A>G, and tHcy,
folate, and vitamin B12 plasma concentrations [9, 20, 29].
In reading this paper, it is important to note that the
present study is but one experiment, one observation that
needs to be confirmed by other studies. It is possible that a
causal relation between these genotypes and mortality or
allograft loss exists, but that the relative risks are too small
to be detected by a study of this size or scope. The 95%
confidence intervals indicate the likely range of the true
population parameters; associations outside these ranges
are not consistent with our data. Hence, a strong causal
relation such as a doubling of risk between MTHFR
677C>T and the outcomes of study appears to be highly
unlikely. For illustration, we would have needed a cohort
of >4000 patients to detect a 25% increase in mortality
risk associated with homozygosity rather than wild-type
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MTHFR677C>T in our study (assuming 80% power).
Unfortunately, we have no information on other impor-
tant end points or possible confounders such as past his-
tory of cardiovascular disease, new-onset diabetes after
transplantation, acute rejection, delayed graft function,
rejection episodes, or nonfatal cardiovascular events. We
cannot rule out that survival bias has contributed to our
findings of no association. If hazards are proportional,
and we have not found any indication for violation of
this assumption, then survival bias should not be a factor.
However, if patients with increased risk that is associ-
ated with the polymorphism(s) of study leave the cohort
prematurely, the concept of “depletion of susceptibles”
may apply [30]. In such a scenario, the null hypothesis
is, indeed, favored. However, the limitations of this study
need to be seen under consideration of the fact that infor-
mation on these genotypes is not available in other large
cohorts or registries of KTR.
CONCLUSION
We conclude for this study that the routine use of
MTHFR or MTRR genotyping for prognostic evaluation
or risk stratification in KTR is currently not warranted.
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